The FDA on Sept. 9 approved Bristol Myers Squibb’s Sotyktu for the treatment of moderate-to-severe plaque psoriasis in adult patients. It’s a first-in-class win for the selective allosteric tyrosine kinase 2 (TYK2) inhibitor. BMS acquired Sotyktu as part of its 2019 merger with Celgene Corporation, with Amgen purchasing Celgene’s extant immunology drug Otezla in order for regulators to approve the deal. But now Otezla may be in trouble with Sotyktu on the market, as the TYK2 inhibitor proved more affective than Otezla in clinical trials. For the treatment of psoriasis, 98% of all insured lives have covered or better access to Otezla under the pharmacy benefit. 8.6% of lives have preferred access to Otezla, growing to 54.3% with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 9/14/22